Glaukos (NYSE:GKOS)‘s stock had its “overweight” rating restated by Stephens in a report issued on Monday, November 13th, The Fly reports. They currently have a $40.00 target price on the medical instruments supplier’s stock, down from their prior target price of $47.00. Stephens’ price target would suggest a potential upside of 51.69% from the stock’s current price.
Other research analysts also recently issued reports about the company. Zacks Investment Research raised Glaukos from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a report on Friday, July 21st. Cantor Fitzgerald reissued a “buy” rating and issued a $60.00 price target (up from $54.00) on shares of Glaukos in a report on Thursday, September 14th. BidaskClub raised Glaukos from a “hold” rating to a “buy” rating in a report on Tuesday, September 12th. BMO Capital Markets reaffirmed a “buy” rating and set a $54.00 target price on shares of Glaukos in a research note on Friday, September 1st. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $56.00 target price on shares of Glaukos in a research note on Thursday, August 3rd. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $46.57.
Glaukos (GKOS) opened at $26.37 on Monday. Glaukos has a twelve month low of $23.44 and a twelve month high of $52.49. The stock has a market capitalization of $911.49 and a P/E ratio of 223.08.
In other news, CFO Joseph E. Gilliam purchased 2,100 shares of the company’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was purchased at an average cost of $23.84 per share, for a total transaction of $50,064.00. Following the completion of the transaction, the chief financial officer now owns 102,100 shares of the company’s stock, valued at $2,434,064. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas William Burns sold 1,212 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $41.25, for a total value of $49,995.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 655,200 shares of company stock valued at $25,573,013. Corporate insiders own 16.40% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of GKOS. Prudential Financial Inc. purchased a new stake in shares of Glaukos during the first quarter worth approximately $204,000. FMR LLC purchased a new stake in shares of Glaukos during the first quarter worth approximately $7,323,000. Teachers Advisors LLC increased its position in shares of Glaukos by 6.2% during the first quarter. Teachers Advisors LLC now owns 29,512 shares of the medical instruments supplier’s stock worth $1,514,000 after purchasing an additional 1,723 shares in the last quarter. California Public Employees Retirement System purchased a new stake in Glaukos in the 1st quarter valued at $390,000. Finally, Vanguard Group Inc. grew its holdings in Glaukos by 17.6% in the 1st quarter. Vanguard Group Inc. now owns 1,612,838 shares of the medical instruments supplier’s stock valued at $82,739,000 after buying an additional 241,772 shares in the last quarter. Hedge funds and other institutional investors own 99.62% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was published by BBNS and is the sole property of of BBNS. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://baseballnewssource.com/markets/stephens-reaffirms-overweight-rating-for-glaukos-corporation-gkos/1781833.html.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with our FREE daily email newsletter.